About Peijia
Corporate Overview
Introduction of Achieva Medical
Milestones
Management Team
Awards and Recognitions
Social Responsibility
Diseases and Solutions
Valvular Heart Diseases
Stroke
Product Center
TAVR
Neurointerventional Procedural Products
Investor Relations
Corporate Information
Prospectus
Financial Reports
Announcements and Circulars
Presentation Materials
Corporate Governance
Investor Enquiries
News Center
Careers
Contact Us
简
繁
About Peijia
Corporate Overview
Introduction of Achieva Medical
Milestones
Management Team
Awards and Recognitions
Social Responsibility
Diseases and Solutions
Valvular Heart Diseases
Stroke
Product Center
TAVR
Neurointerventional Procedural Products
Investor Relations
Corporate Information
Prospectus
Financial Reports
Announcements and Circulars
Presentation Materials
Corporate Governance
Investor Enquiries
News Center
Careers
Contact Us
简
繁
About Peijia
Corporate Overview
Introduction of Achieva Medical
Milestones
Management Team
Awards and Recognitions
Social Responsibility
Diseases and Solutions
Valvular Heart Diseases
Stroke
Product Center
TAVR
Neurointerventional Procedural Products
Investor Relations
Corporate Information
Prospectus
Financial Reports
Announcements and Circulars
Presentation Materials
Corporate Governance
Investor Enquiries
News Center
Careers
Contact Us
News Center
Peijia Medical Announced 2021 Annual Results
2022-04-06
NMPA Approval for Registration Application of Syphonet®️ Stent Retriever
2022-02-17
Peijia Medical Obtained Exclusive License for JenaValve
2022-02-07
The First Clinical Case using HighLife Transseptal Mitral Valve Replacement Technology was Successfully Carried out in Asia
2022-01-08
Peijia Medical Announces First Patient Treatment in the Clinical Trial of its Innovative Non-implant TaurusWave® Lithotripsy Valvuloplasty System
2021-11-01
Peijia Medical Announces First Patient Implant in the Clinical Trial of its Third-Generation Transcatheter Aortic Valve System TaurusNXT®
2021-09-14
Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant To Advise the Company’s Mitral Transcatheter Edge-to-edge Repair Project and the Company in General
2021-09-06
Peijia Medical Announces 2021 Interim Results
2021-08-31
TaurusOne Valve clinical outcome published in EuroIntervention
2021-08-09
With the second-generation transcatheter aortic valve replacement system approved for marketing, Peijia Medical leads China into the “Retrievable Era” using TAVR products
2021-06-26
Peijia Medical and CR PHARMA COMM Sign Memorandum of Strategic Cooperation
2021-06-25
Peijia Medical Partners with inQB8 for US Incubator and Transcatheter Tricuspid Replacement (TTVR) Product
2021-06-10
Peijia Medical and CR PHARMA COMM Sign Memorandum of Strategic Cooperation
2021-06-04
Peijia Medical’s TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization
2021-04-26
Patient Enrollment Completed for Clinical Trial of Peijia Medical’s Shenyi® Stent Retriever
2021-02-01
Collaboration Strengthens Peijia’s Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLife’s Technology
2020-12-21
Peijia Medical Successfully Commenced Animal Study for its Mitral Valve Edge-to-Edge Repair Product
2020-12-04
Peijia Medical Successfully Listed on the Main Board of the Stock Exchange of Hong Kong
2020-05-15
Peijia Medical Announces Global Offering Results Offer Price is HK$15.36 per Offer Share, Commence Trading on the Main Board of the Hong Kong Stock Exchange On May 15, 2020
2020-05-14
Peijia Medical Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange
2020-05-05